Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

The role of margins in extremity soft tissue sarcoma.

Byerly S, Chopra S, Nassif NA, Chen P, Sener SF, Eisenberg BL, Tseng WW.

J Surg Oncol. 2016 Mar;113(3):333-8. doi: 10.1002/jso.24112. Epub 2015 Dec 10. Review.

PMID:
26662660
2.

Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas.

Chinyengetere F, Sekula DJ, Lu Y, Giustini AJ, Sanglikar A, Kawakami M, Ma T, Burkett SS, Eisenberg BL, Wells WA, Hoopes PJ, Demicco EG, Lazar AJ, Torres KE, Memoli V, Freemantle SJ, Dmitrovsky E.

BMC Cancer. 2015 Nov 10;15:886. doi: 10.1186/s12885-015-1883-8.

3.

Contemporary Management of Retroperitoneal Soft Tissue Sarcomas.

Olimpiadi Y, Song S, Hu JS, Matcuk GR, Chopra S, Eisenberg BL, Sener SF, Tseng WW.

Curr Oncol Rep. 2015 Aug;17(8):39. doi: 10.1007/s11912-015-0462-0. Review.

PMID:
26092408
4.

Significant Reduction of Late Toxicities in Patients With Extremity Sarcoma Treated With Image-Guided Radiation Therapy to a Reduced Target Volume: Results of Radiation Therapy Oncology Group RTOG-0630 Trial.

Wang D, Zhang Q, Eisenberg BL, Kane JM, Li XA, Lucas D, Petersen IA, DeLaney TF, Freeman CR, Finkelstein SE, Hitchcock YJ, Bedi M, Singh AK, Dundas G, Kirsch DG.

J Clin Oncol. 2015 Jul 10;33(20):2231-8. doi: 10.1200/JCO.2014.58.5828. Epub 2015 Feb 9.

5.

Estrogen receptor alpha and androgen receptor are commonly expressed in well-differentiated liposarcoma.

Ingram DR, Dillon LM, Lev DC, Lazar A, Demicco EG, Eisenberg BL, Miller TW.

BMC Clin Pathol. 2014 Oct 22;14:42. doi: 10.1186/1472-6890-14-42. eCollection 2014.

6.

A proof of principle clinical trial to determine whether conjugated linoleic acid modulates the lipogenic pathway in human breast cancer tissue.

McGowan MM, Eisenberg BL, Lewis LD, Froehlich HM, Wells WA, Eastman A, Kuemmerle NB, Rosenkrantz KM, Barth RJ Jr, Schwartz GN, Li Z, Tosteson TD, Beaulieu BB Jr, Kinlaw WB.

Breast Cancer Res Treat. 2013 Feb;138(1):175-83. doi: 10.1007/s10549-013-2446-9. Epub 2013 Feb 16.

7.

The SSG XVIII/AIO trial: results change the current adjuvant treatment recommendations for gastrointestinal stromal tumors.

Eisenberg BL.

Am J Clin Oncol. 2013 Feb;36(1):89-90. doi: 10.1097/COC.0b013e31827a7f55.

PMID:
23334483
8.

Gastrointestinal stromal tumor--background, pathology, treatment.

Eisenberg BL, Pipas JM.

Hematol Oncol Clin North Am. 2012 Dec;26(6):1239-59. doi: 10.1016/j.hoc.2012.08.003. Review.

PMID:
23116579
9.

Thromboembolic Events Associated with Thalidomide and Multimodality Therapy for Soft Tissue Sarcomas: Results of RTOG 0330.

Kane JM 3rd, Harris J, Kraybill WG, Harmon DC, Ettinger DS, Lucas DR, Delaney TF, Wang D, Curran WJ, Eisenberg BL.

Sarcoma. 2012;2012:659485. doi: 10.1155/2012/659485. Epub 2012 Apr 24.

10.

Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.

Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M, Eisenberg BL.

Ann Surg Oncol. 2012 Apr;19(4):1074-80. doi: 10.1245/s10434-011-2190-5. Epub 2011 Dec 28. Erratum in: Ann Surg Oncol. 2012 Jul;19(7):2420.

11.

Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors.

Eisenberg BL, Trent JC.

Int J Cancer. 2011 Dec 1;129(11):2533-42. doi: 10.1002/ijc.26234. Review.

12.

Lipoprotein lipase links dietary fat to solid tumor cell proliferation.

Kuemmerle NB, Rysman E, Lombardo PS, Flanagan AJ, Lipe BC, Wells WA, Pettus JR, Froehlich HM, Memoli VA, Morganelli PM, Swinnen JV, Timmerman LA, Chaychi L, Fricano CJ, Eisenberg BL, Coleman WB, Kinlaw WB.

Mol Cancer Ther. 2011 Mar;10(3):427-36. doi: 10.1158/1535-7163.MCT-10-0802. Epub 2011 Jan 31.

13.

Adjuvant and neoadjuvant therapy for primary GIST.

Eisenberg BL, Smith KD.

Cancer Chemother Pharmacol. 2011 Jan;67 Suppl 1:S3-8. doi: 10.1007/s00280-010-1516-5. Epub 2010 Nov 30. Review.

PMID:
21116626
14.

Fatty acid synthesis is a therapeutic target in human liposarcoma.

Olsen AM, Eisenberg BL, Kuemmerle NB, Flanagan AJ, Morganelli PM, Lombardo PS, Swinnen JV, Kinlaw WB.

Int J Oncol. 2010 May;36(5):1309-14.

15.

High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors.

Belinsky MG, Skorobogatko YV, Rink L, Pei J, Cai KQ, Vanderveer LA, Riddell D, Merkel E, Tarn C, Eisenberg BL, von Mehren M, Testa JR, Godwin AK.

Genes Chromosomes Cancer. 2009 Oct;48(10):886-96. doi: 10.1002/gcc.20689.

16.

Conjugated linoleic acid (CLA) inhibits expression of the Spot 14 (THRSP) and fatty acid synthase genes and impairs the growth of human breast cancer and liposarcoma cells.

Donnelly C, Olsen AM, Lewis LD, Eisenberg BL, Eastman A, Kinlaw WB.

Nutr Cancer. 2009;61(1):114-22. doi: 10.1080/01635580802348666.

17.

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M.

J Surg Oncol. 2009 Jan 1;99(1):42-7. doi: 10.1002/jso.21160.

18.

The synthetic triterpenoid CDDO-Im inhibits fatty acid synthase expression and has antiproliferative and proapoptotic effects in human liposarcoma cells.

Hughes DT, Martel PM, Kinlaw WB, Eisenberg BL.

Cancer Invest. 2008 Mar;26(2):118-27. doi: 10.1080/07357900701522612.

19.

Combined-modality strategy for gastrointestinal stromal tumors.

Eisenberg BL.

Semin Oncol. 2006 Dec;33(6 Suppl 11):S75-8. Review.

PMID:
17178293
20.

Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ Jr, Eisenberg BL, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Reaman GH, Sawaya R, Schilsky RL, Schuchter LM, Sweetenham JW, Vahdat LT, Winn RJ; American Society of Clinical Oncology.

J Clin Oncol. 2007 Jan 1;25(1):146-62. Epub 2006 Dec 8.

PMID:
17158528
21.

Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trials.

Eisenberg BL.

Clin Colorectal Cancer. 2006 Nov;6 Suppl 1:S24-9. Review.

PMID:
17101065
22.

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA.

J Clin Oncol. 2006 Oct 10;24(29):4764-74. Epub 2006 Sep 5.

PMID:
16954519
23.

Epidemiology of GIST.

Blanke C, Eisenberg BL, Heinrich M.

Am J Gastroenterol. 2005 Oct;100(10):2366. No abstract available.

PMID:
16181397
24.

Soft tissue sarcomas: opportunities for defining the molecular phenotype of a solid tumor malignancy.

Eisenberg BL.

Curr Opin Oncol. 2005 Jul;17(4):355-6. No abstract available.

PMID:
15933467
25.

The association of cytokeratin-only-positive sentinel lymph nodes and subsequent metastases in breast cancer.

Mullenix PS, Brown TA, Meyers MO, Giles LR, Sigurdson ER, Boraas MC, Hoffman JP, Eisenberg BL, Torosian MH.

Am J Surg. 2005 May;189(5):606-9; discussion 609.

PMID:
15862505
26.

Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients.

Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg BL, Cairns P.

Cancer Res. 2004 Sep 15;64(18):6476-81.

27.

Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome.

Sasson AR, Wetherington RW, Hoffman JP, Ross EA, Cooper H, Meropol NJ, Freedman G, Pingpank JF, Eisenberg BL.

Int J Gastrointest Cancer. 2003;34(2-3):121-8.

PMID:
15361645
28.

Soft tissue sarcomas treated with postoperative external beam radiotherapy with and without low-dose-rate brachytherapy.

Andrews SF, Anderson PR, Eisenberg BL, Hanlon AL, Pollack A.

Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):475-80.

PMID:
15145165
29.

Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.

Eisenberg BL, Judson I.

Ann Surg Oncol. 2004 May;11(5):465-75. Review.

PMID:
15123459
30.

NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines.

Demetri GD, Benjamin R, Blanke CD, Choi H, Corless C, DeMatteo RP, Eisenberg BL, Fletcher CD, Maki RG, Rubin BP, Van den Abbeele AD, von Mehren M; NCCN GIST Task Force.

J Natl Compr Canc Netw. 2004 May;2 Suppl 1:S-1-26; quiz 27-30.

PMID:
23573667
31.

Is reporting of recurrence data important in pancreatic cancer?

Meyers MO, Meszoely IM, Hoffman JP, Watson JC, Ross E, Eisenberg BL.

Ann Surg Oncol. 2004 Mar;11(3):304-9.

PMID:
14993026
32.

Intraoperative radiotherapy in the multimodality approach to bone and soft tissue cancers.

Ellis RJ, Kim E, Kinsella TJ, Eisenberg BL.

Surg Oncol Clin N Am. 2003 Oct;12(4):1015-29. Review.

PMID:
14989130
33.

Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors.

Eisenberg BL.

Oncology (Williston Park). 2003 Nov;17(11):1615-20; discussion 1620, 1623, 1626 passim. Review.

34.

Soft tissue sarcomas of adults: state of the translational science.

Borden EC, Baker LH, Bell RS, Bramwell V, Demetri GD, Eisenberg BL, Fletcher CD, Fletcher JA, Ladanyi M, Meltzer P, O'Sullivan B, Parkinson DR, Pisters PW, Saxman S, Singer S, Sundaram M, van Oosterom AT, Verweij J, Waalen J, Weiss SW, Brennan MF.

Clin Cancer Res. 2003 Jun;9(6):1941-56. Review.

35.

Pharmacotherapy of gastrointestinal stromal tumours.

Eisenberg BL, von Mehren M.

Expert Opin Pharmacother. 2003 Jun;4(6):869-74. Review.

PMID:
12783584
36.

Gastrointestinal stromal tumors.

Blanke CD, Eisenberg BL, Heinrich MC.

Curr Treat Options Oncol. 2001 Dec;2(6):485-91. Review.

PMID:
12057094
37.

En bloc resection for locally advanced cancer of the pancreas: is it worthwhile?

Sasson AR, Hoffman JP, Ross EA, Kagan SA, Pingpank JF, Eisenberg BL.

J Gastrointest Surg. 2002 Mar-Apr;6(2):147-57; discussion 157-8.

PMID:
11992799
38.

Pancreatic resection for locally advanced primary and metastatic nonpancreatic neoplasms.

Pingpank JF Jr, Hoffman JP, Sigurdson ER, Ross E, Sasson AR, Eisenberg BL.

Am Surg. 2002 Apr;68(4):337-40; discussion 340-1.

PMID:
11952243
39.

Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation.

Sasson AR, Fowble B, Hanlon AL, Torosian MH, Freedman G, Boraas M, Sigurdson ER, Hoffman JP, Eisenberg BL, Patchefsky A.

Cancer. 2001 May 15;91(10):1862-9.

PMID:
11346867
40.

Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas.

Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G, Pinover WH, LeVoyer TE, Sasson AR, Eisenberg BL.

J Gastrointest Surg. 2001 Mar-Apr;5(2):121-30.

PMID:
11331473
41.

Local recurrence of breast cancer in the stereotactic core needle biopsy site: case reports and review of the literature.

Chao C, Torosian MH, Boraas MC, Sigurdson ER, Hoffman JP, Eisenberg BL, Fowble B.

Breast J. 2001 Mar-Apr;7(2):124-7. Review.

PMID:
11328321
42.

Trimodality therapy for advanced gallbladder cancer.

Sasson AR, Hoffman JP, Ross E, Meropol NJ, Szarka CE, Freedman G, Pinover W, Pingpank JF, Eisenberg BL.

Am Surg. 2001 Mar;67(3):277-83; discussion 284.

PMID:
11270889
43.

Pancreatic carcinoma deemed unresectable at exploration may be resected for cure: an institutional experience.

Chao C, Hoffman JP, Ross EA, Torosian MH, Eisenberg BL.

Am Surg. 2000 Apr;66(4):378-85; discussion 386. Review.

PMID:
10776876
44.

Biliary CA 19-9 values correlate with the risk of hepatic metastases in patients with adenocarcinoma of the pancreas.

Montgomery RC, Hoffma JP, Ross EA, Riley LB, Ridge JA, Eisenberg BL.

J Gastrointest Surg. 1998 Jan-Feb;2(1):28-35.

PMID:
9841965
45.

Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer.

Movsas B, Hanlon AL, Lanciano R, Scher RM, Weiner LM, Sigurdson ER, Hoffman JP, Eisenberg BL, Cooper HS, Provins S, Coia LR.

Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):43-50.

PMID:
9747818
46.

Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma.

Pendurthi TK, Hoffman JP, Ross E, Johnson DE, Eisenberg BL.

Am Surg. 1998 Jul;64(7):686-92.

PMID:
9655283
47.

A close or positive margin after mastectomy is not an indication for chest wall irradiation except in women aged fifty or younger.

Freedman GM, Fowble BL, Hanlon AL, Myint MA, Hoffman JP, Sigurdson ER, Eisenberg BL, Goldstein LJ, Fein DA.

Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):599-605.

PMID:
9635708
48.

Comparison of liver function tests after hepatic lobectomy and hepatic wedge resection.

Pelton JJ, Hoffman JP, Eisenberg BL.

Am Surg. 1998 May;64(5):408-14.

PMID:
9585773
49.

Use of saline-filled tissue expanders to protect the small bowel from radiation.

Hoffman JP, Sigurdson ER, Eisenberg BL.

Oncology (Williston Park). 1998 Jan;12(1):51-4; discussion 54, 60, 62, passim. Erratum in: Oncology (Huntingt) 1998 Mar;12(3):421.

50.

Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas.

Montgomery RC, Hoffman JP, Riley LB, Rogatko A, Ridge JA, Eisenberg BL.

Ann Surg Oncol. 1997 Oct-Nov;4(7):551-6.

PMID:
9367020

Supplemental Content

Loading ...
Support Center